Detalhe da pesquisa
1.
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.
N Engl J Med
; 388(6): 489-498, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780674
2.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
N Engl J Med
; 386(21): 1973-1985, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403841
3.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Future Oncol
; 19(8): 549-557, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815433
4.
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.
Br J Cancer
; 127(8): 1497-1506, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945244
5.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35641218
6.
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
BMC Cancer
; 22(1): 17, 2022 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980038
7.
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Lancet Oncol
; 22(5): 727-736, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862002
8.
Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Oncologist
; 26(1): 40-48, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32864799
9.
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Lancet Oncol
; 21(12): 1589-1601, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125909
10.
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Cancer
; 126(14): 3237-3243, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365226
11.
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Cancer
; 126(10): 2146-2152, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32073648
12.
A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
Cancer
; 125(3): 382-390, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343497
13.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31246283
14.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718784
15.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29533458
16.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866947
17.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028407
18.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
19.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28651929
20.
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Oncologist
; 22(2): 189-198, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188257